Source:http://linkedlifedata.com/resource/pubmed/id/11223969
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2001-3-6
|
| pubmed:abstractText |
Data from 170 consecutive patients aged 19-66 years (median age 46 years) who underwent unmanipulated autologous blood stem cell transplant (ASCT) were analyzed to determine if total CD34+ cells/kg infused, CD34+ subsets (CD34+41+, CD34+90+, CD34+33-, CD34+38-, CD34+38-DR-), peripheral blood CD34+ cell (PBCD34+) count on first apheresis day, or various clinical factors were associated with low blood counts 6 months post ASCT. Thirty-four patients were excluded from analysis either because of death (n = 17) or re-induction chemotherapy prior to 6 months post ASCT (n = 13), or because of lack of follow-up data (n = 4). Of the remaining 136 patients, 46% had low WBC ( < 4 x 10(9)/l), 41% low platelets (<150 x 10(9)/l), and 34% low hemoglobin ( < 120 g/l) at a median of 6 months following ASCT. By Spearman's rank correlation, both the total CD34+ cell dose/kg and the PBCD34+ count correlated with 6 month blood counts better than any subset of CD34+ cells or any clinical factor. The PBCD34+ count was overall a stronger predictor of 6 month blood counts than was the total CD34+ cells/kg infused. Both factors retained their significance in multivariate analysis, controlling for clinical factors. In conclusion, subsets of CD34+ cells and clinical factors are inferior to the total CD34+ cell dose/kg and PBCD34+ count in predicting 6 month blood counts following ASCT.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
26
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1299-304
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:11223969-Adult,
pubmed-meshheading:11223969-Aged,
pubmed-meshheading:11223969-Antigens, CD34,
pubmed-meshheading:11223969-Blood Cell Count,
pubmed-meshheading:11223969-Blood Transfusion, Autologous,
pubmed-meshheading:11223969-Female,
pubmed-meshheading:11223969-Follow-Up Studies,
pubmed-meshheading:11223969-Graft Survival,
pubmed-meshheading:11223969-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11223969-Humans,
pubmed-meshheading:11223969-Immunophenotyping,
pubmed-meshheading:11223969-Male,
pubmed-meshheading:11223969-Middle Aged,
pubmed-meshheading:11223969-Neoplasms,
pubmed-meshheading:11223969-Predictive Value of Tests,
pubmed-meshheading:11223969-Prognosis,
pubmed-meshheading:11223969-Retrospective Studies,
pubmed-meshheading:11223969-Statistics, Nonparametric,
pubmed-meshheading:11223969-Transplantation, Autologous
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Predictive factors for long-term engraftment of autologous blood stem cells.
|
| pubmed:affiliation |
Department of Medicine, Tom Baker Cancer Center, Foothills Hospital, and University of Calgary, Calgary, Alberta, Canada.
|
| pubmed:publicationType |
Journal Article
|